Please login to the form below

Not currently logged in
Email:
Password:

Andrew Witty appointed president of EFPIA

The European Federation of Pharmaceutical Industries and Associations has appointed Andrew Witty, CEO of GlaxoSmithKline, as its new president

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has appointed Andrew Witty, CEO of GlaxoSmithKline (GSK), as its new president. Witty will succeed outgoing president, Arthur Higgins, CEO of Bayer Healthcare.

 

Andrew Witty

 Andrew Witty
 


Commenting on his appointment, Witty said: "I am pleased to have the opportunity to represent our industry in Europe at this challenging time, when the policy considerations of healthcare have probably never been more pertinent. I thank Arthur Higgins for the focus he brought to the role of president, and the solid base it provides. As a result of his efforts, we are well prepared for future engagement and cooperation with the new Commission, European Parliament, Member States, patients and other stakeholders."

Witty, who has been vice-president of the EFPIA since 2008, went on to say: "Europe needs a 21st century approach to healthcare; one that provides access to optimal and equitable quality of care in a manner that is sustainable. We need policies that make this a reality, as well as policies that recognise innovation, equipping us to develop new medicines and therapies that citizens seek."

Higgins is also relinquishing his post at Bayer, for personal reasons. He is expected to be replaced by Marijn Dekkers, formerly of Thermo Fisher Scientific.

7th January 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics